The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

The first-of-its-kind Edwards Lifesciences Sapien M3 TMVR system uses a nitinol dock to anchor the replacement valve in the ...

Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

Cardiac Dimensions has secured $53m in a Series E funding round to support its ongoing pivotal trial assessing the company’s mitral valve repair device. The round was led by investment ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter ...

Mitral regurgitation is the most common form of valvular heart disease and affects around 10% of Americans over 75. It occurs when the mitral ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

Where this device will fit in with other emerging options remains to be seen, but it might hold an advantage in large annuli.

Transcatheter valve replacement technologies have been ... The largest markets for these devices include aortic and mitral valve replacements. The transcatheter tricuspid valve device market ...

Edwards Lifesciences has received Europe’s CE mark for its transcatheter mitral valve replacement system, Sapien M3, the company said Monday. The device is designed for people with symptomatic ...

Edwards SAPIEN M3 mitral valve replacement system receives CE Mark for transcatheter treatment: Irvine, California Wednesday, ...